Professor, Medicine, University of Alabama School of Medicine
Hematology
Dr. Albert F. Lobuglio, MD
|
|
Give Review
Albert F. Lobuglio, MD is an expert in the field of Hematology. He graduated from Georgetown University School of Medicine. Georgetown University School of Medicine has a rank of 49 in research and a 84 in primary care He received 1 awards: "Elected Member". Albert Lobuglio is a published physician as well. He has 101 publications published. The latest was: Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen.
Publications
- Recurrent read-through fusion transcripts in breast cancer.
- Effect of niclosamide on basal-like breast cancers.
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.
- Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.
- Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
- Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
- Cellular model of warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin.
- Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
- Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
- Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone rec...
- Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
- Epithelial transformation by KLF4 requires Notch1 but not canonical Notch1 signaling.
- Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
- Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
- A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.
- TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
- Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies.
- Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
- Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin''s lymphoma.
- TRAIL-receptor antibodies as a potential cancer treatment.
- Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
- A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.
- Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.
- Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.
- Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death d...
- TRAIL receptor-targeted therapy.
- Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid ad...
- Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
- Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
- Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
- Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
- Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.
- Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
- Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
- The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3.
- Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.
- Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.
- ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
- Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II...
- Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
- Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer.
- History of antibody therapy for non-Hodgkin's lymphoma.
- A novel monoclonal antibody design for radioimmunotherapy.
- Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
- Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.
- Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologi...
- Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.
- A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
- Invited commentary: targeting of 125I-labeled B lymphocyte stimulator.
- A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
- A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
- Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
- Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
- A non-invasive approach for monitoring breast tumor cells during therapeutic intervention.
- Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
- Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
- Expression of human endogenous retrovirus k envelope transcripts in human breast cancer.
- A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.
- Clearing of cells bearing the bcl-2 t(14;18) translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
- A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
- Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers.
- Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
- Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine.
- SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma.
- Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine.
- Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
- Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administrat...
- Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
- Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen.
- Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease.
- Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells.
- Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy.
- Recent progress in radioimmunotherapy for cancer.
- Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
- Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.
- Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.
- Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
- Polynucleotide-mediated immunization therapy of cancer.
- Selected strategies to augment polynucleotide immunization.
- Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer.
- Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
- Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointest...
- Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.
- CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor.
- A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo.
- Characterization of a messenger RNA polynucleotide vaccine vector.
- A carcinoembryonic antigen polynucleotide vaccine for human clinical use.
- A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity.
- Characterization of poliovirus replicons encoding carcinoembryonic antigen.
- Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas.
- Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.
- Immune response to a carcinoembryonic antigen polynucleotide vaccine.
- Human immune response to monoclonal antibodies.
- Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study.
- A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
- An animal model to predict the immunogenicity of murine V regions in humans.
- Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.
- Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis.
- Chimeric antibodies.
- A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
Schools
Georgetown University
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- MultiPlan PPO
Awards
- Elected Member
Education
-
Boston University Medical Center -
University of Pittsburgh Medical Center -
Georgetown University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Jimmie H. Harvey Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kelly N. Godby, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christos Vaklavas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donna E. Salzman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katisha T. Vance, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Uma M. Borate, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiaojun Wu, MD |
|
|
Dr. David L. Jaye, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charlie W. Scott Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc E. Usrey, MD |
|
|
Dr. John L. Hartman IV, MD |
|
|
Dr. Taylor M. Deal, MD |
|
|
Dr. Randall S. Davis, MD |